Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.

Suppr

超能文献

作者信息

Moore M R, Troner M B, DeSimone P, Birch R, Irwin L

出版信息

Cancer Treat Rep. 1986 Apr;70(4):541-2.

PMID:3698053

Abstract

摘要

相似文献

Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.

Cancer Treat Rep. 1986 Apr;70(4):541-2.

Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.

Cancer Treat Rep. 1987 Jan;71(1):89-90.

Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.

Prog Clin Biol Res. 1985;185A:251-70.

Melphalan in metastatic cancer of the prostate: a pilot study.

Cancer Treat Rep. 1979 Feb;63(2):228-9.

European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.欧洲癌症研究与治疗组织（EORTC）关于低剂量每周一次表柔比星治疗转移性前列腺癌的II期研究。

Cancer Treat Rep. 1987 Dec;71(12):1317-8.

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.紫杉醇联合每周大剂量5-氟尿嘧啶/亚叶酸钙和顺铂治疗晚期乳腺癌。

Semin Oncol. 1996 Oct;23(5 Suppl 11):32-7.

Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.基于前列腺特异性抗原和碱性磷酸酶早期系列测量对转移性前列腺癌生存情况的预测

J Urol. 2008 Jan;179(1):117-22; discussion 122-3. doi: 10.1016/j.juro.2007.08.132. Epub 2007 Nov 12.

Metastatic prostate carcinoma to the mandible: report of case.

J Oral Surg. 1977 Feb;35(2):133-5.

[Treatment of advanced prostatic carcinoma with cis-diamminedichloroplatinum].

Hinyokika Kiyo. 1984 Dec;30(12):1801-7.

Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study.顺铂用于转移性前列腺癌的II期研究。一项东部肿瘤协作组的研究。

Am J Clin Oncol. 1983 Apr;6(2):203-5. doi: 10.1097/00000421-198304000-00011.

引用本文的文献

The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells.非对称手性 CCN 夹镍配合物作为靶向前列腺癌细胞的化学治疗剂的新功能。

Molecules. 2022 May 12;27(10):3106. doi: 10.3390/molecules27103106.

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.卡铂-紫杉烷类联合方案在去势抵抗性前列腺癌治疗中的疗效：7 项前瞻性临床试验的汇总分析。

Ann Oncol. 2010 Feb;21(2):312-318. doi: 10.1093/annonc/mdp308. Epub 2009 Jul 24.

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.沙他铂治疗激素难治性转移性前列腺癌。

Ther Clin Risk Manag. 2007 Oct;3(5):877-83.

Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?去势抵抗性前列腺癌（AIPC）中的化疗：紫杉烷治疗进展后下一步该如何？

Cancer Ther. 2007;5A(A):151-160.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.一项针对晚期实体瘤患者的Ⅰ期药代动力学研究，每两周对患者进行一次30分钟的伊罗氟文和顺铂静脉输注。

Invest New Drugs. 2006 Jul;24(4):311-9. doi: 10.1007/s10637-005-5055-6.

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).口服双（乙酰）氨二氯（环己胺）铂（IV）（JM - 216，BMS - 182751）每日给药5天用于激素难治性前列腺癌（HRPC）的II期研究。

Invest New Drugs. 2005 Jan;23(1):79-84. doi: 10.1023/B:DRUG.0000047109.76766.84.

Beta-galactosidase as a marker of HSP70 promoter induction in Dunning R3327 prostate carcinoma cells.β-半乳糖苷酶作为邓宁R3327前列腺癌细胞中HSP70启动子诱导的标志物。

Urol Res. 1997;25(4):251-5. doi: 10.1007/BF00942094.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验